4//SEC Filing
Xu Diyong 4
Accession 0000950170-25-028260
CIK 0001661998other
Filed
Feb 25, 7:00 PM ET
Accepted
Feb 26, 9:59 PM ET
Size
9.2 KB
Accession
0000950170-25-028260
Insider Transaction Report
Form 4
Q32 Bio Inc.QTTB
Xu Diyong
Director
Transactions
- Award
Stock Option (Right to Buy)
2025-02-24+12,767→ 12,767 totalExercise: $2.54Exp: 2034-03-24→ Common Stock (12,767 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2025-02-24−12,767→ 0 totalExercise: $16.82Exp: 2034-03-24→ Common Stock (12,767 underlying)
Footnotes (4)
- [F1]On February 24, 2025, the Issuer's board of directors approved an option repricing ("Repricing Date"). All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
- [F2]This stock option award was issued pursuant to the Q32 Bio Inc. 2017 Stock Option and Grant Plan (the "2017 Plan") or the Q32 Bio Inc. 2024 Stock Option and Incentive Plan (the "2024 Plan"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
- [F3]Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VII, LP.
- [F4]The exercise price of the option is $2.54 per share, representing the fair market value per share of the Issuer's Common Stock on the Repricing Date; provided that in the event (i) the option is exercised prior to the one-year anniversary of the Repricing Date, (ii) the Reporting Person's employment is terminated by the Company prior to the one-year anniversary of the Repricing Date due to Cause (as defined in the 2024 Plan) or (iii) the Reporting Person resigns for any reason prior to the one-year anniversary of the Repricing Date, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted.
Documents
Issuer
Q32 Bio Inc.
CIK 0001661998
Entity typeother
Related Parties
1- filerCIK 0001995088
Filing Metadata
- Form type
- 4
- Filed
- Feb 25, 7:00 PM ET
- Accepted
- Feb 26, 9:59 PM ET
- Size
- 9.2 KB